XenoTherapeutics to Acquire ESSA Pharma in US$1.91/Share Deal Plus CVRs

Introduction

ESSA Pharma Inc (NASDAQ: EPIX) is a clinical-stage pharmaceutical company headquartered in Vancouver, British Columbia. The company focuses on discovering and developing small-molecule therapies for prostate cancer by targeting the androgen receptor’s N-terminal domain. Its lead investigational candidate, masofaniten (formerly EPI-7386), aims to disrupt androgen receptor signaling, which is implicated in tumor growth in prostate cancer.

Corporate Structure and Experience

ESSA Pharma employs between 11 and 50 staff members, reflecting a focused research and development organization. Since 2016, David Parkinson, M.D., has served as President and Chief Executive Officer; he brings over 30 years of clinical oncology development experience, having held senior roles at Biogen, Amgen, and Novartis. Michael Wood has been Chief Financial Officer since 2013, contributing over 30 years of finance experience and more than 18 years in biopharmaceutical management. The board includes Jonathan Glickman, Ph.D., a healthcare entrepreneur who has co-founded multiple biotech companies.

Prostate cancer by National Cancer Institute

Recent Developments and News

On July 14, 2025, ESSA Pharma announced a definitive agreement for acquisition by XenoTherapeutics, Inc., with financing provided by XOMA Royalty Corporation. Under the terms, ESSA shareholders will receive a cash payment estimated at US$1.91 per share, plus one contingent value right (CVR) per share, entitling holders to up to US$0.06 per CVR within 18 months of closing. The transaction will be implemented by a court-approved plan of arrangement under British Columbia’s Business Corporations Act, and it requires shareholder and court approvals, with an expected closing in the second half of 2025. On August 25, 2025, the company filed a definitive proxy statement (DEFA14A) and a current report on Form 8-K with the SEC regarding its transaction committee recommendations and related corporate governance matters.

Financial and Strategic Analysis

As of August 26, 2025, ESSA Pharma’s shares traded at US$0.2515, reflecting a 67.91% decline compared to the prior close. The company’s market capitalization stood at approximately US$37.1 million. Trailing twelve-month results indicate a net loss of US$25.3 million and a diluted EPS of –US$0.57. Total cash reserves were reported at US$109.6 million for the most recent quarter, with negative levered free cash flow of US$14.6 million. The acquisition by XenoTherapeutics is anticipated to expedite shareholder returns and facilitate the wind-down of ESSA’s operations, while its N-terminal domain AR inhibitor platform aims to address mechanisms of resistance that current antiandrogen therapies do not.

Market Position and Industry Context

Prostate cancer treatments currently focus on inhibiting the androgen receptor’s ligand-binding domain, often leading to therapeutic resistance. ESSA Pharma’s approach targets the N-terminal domain, a mechanism not addressed by marketed antiandrogen drugs. Its Phase 1/2 pipeline, including combination trials with existing therapies, places the company among a small number of firms pursuing first-in-class AR inhibitors. Collaboration agreements with Bayer, Janssen, and Astellas integrate its candidate into broader oncology development efforts. Despite its smaller size, ESSA operates within a competitive oncology market where larger pharmaceutical and biotech firms are advancing prostate cancer therapeutics.

tl;dr

On July 14, 2025, ESSA Pharma agreed to be acquired by XenoTherapeutics, with financing by XOMA Royalty. Shareholders are expected to receive approximately US$1.91 per share in cash, plus CVRs worth up to US$0.06 each. The transaction, pending shareholder and court approvals, is anticipated to close in the second half of 2025, after which ESSA will wind down its operations and distribute remaining cash reserves.